Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a once-daily antibiotic dose beat the standard twice-daily regimen in ICU?

NCT ID NCT07258225

Disease control Sponsor: Air Force Specialized Hospital, Cairo, Egypt Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a once-daily dose of the antibiotic tigecycline to the usual twice-daily schedule in 86 critically ill adults with multidrug-resistant infections. The goal is to see if the simpler regimen works just as well or better at clearing the infection and reducing side effects. Participants are in the ICU and must be 18 or older with certain infections like pneumonia or skin infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 86 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Both males and females. * Diagnosis of infection has been established and tigecycline use is indicated (intra-abdominal, community-acquired pneumonia, skin Infections) or based on genetic testing and microbiological cultures (MDR Acinetobacter, MDR Stenotrophomonas, MDR Enterobacteriaceae, etc.) Exclusion Criteria: * Pregnancy and lactation. * Bloodstream infections (BSI) and urinary tract infections (UTIs). * Refusal of attending staff or patient, or family. * Contraindications to tigecycline, such as hypersensitivity and allergy. * Patients receiving ≤ 1 day of tigecycline (insufficient length of therapy). * Patients who have acute physiology and chronic health evaluation (APACHE 2) score of more than 35 (high risk of mortality). * Do not resuscitate/do not intubate (DNR, DNI) patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multi drug resistant infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multi drug resistant infections

Contacts and locations

Locations

  • Air force specialized hospital

    Cairo, Cairo Governorate, 11765, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.